- Home
- FGI vs BLRX Comparison
FGI vs BLRX Comparison
Compare FGI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FGI | BLRX |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Israel |
| Employees | 420 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 12.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | FGI | BLRX |
|---|---|---|
| Price | $3.93 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 8.0K | ★ 9.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $2.30 |
| 52 Week High | $12.62 | $7.77 |
Technical Indicators
Market Signals| Indicator | FGI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 41.70 |
| Support Level | $3.88 | $2.66 |
| Resistance Level | $4.65 | $3.11 |
| Average True Range (ATR) | 0.47 | 0.18 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 32.89 | 23.92 |
Price Performance
Historical ComparisonAbout FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.